<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065075</url>
  </required_header>
  <id_info>
    <org_study_id>H00012082</org_study_id>
    <nct_id>NCT03065075</nct_id>
  </id_info>
  <brief_title>Effect of Phenazopyridine on Prolapse Surgery Voiding Trials</brief_title>
  <acronym>EPOV</acronym>
  <official_title>Effect of Phenazopyridine on Prolapse Surgery Voiding Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if phenazopyridine reduces the rate of postoperative urinary retention after
      pelvic organ prolapse surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several tools can be used to evaluate for ureteral patency during urogynecologic procedures.
      Typically, surgeons use urine dyes such as methylene blue, indigotindisulfonate sodium, or
      phenazopyridine, with the latter being restricted to oral administration. However in June
      2014, the two U.S. manufacturers of indigotindisulfonate sodium stopped producing the
      medication and there is no prospect that it will be returning soon. Phenazopyridine is an
      over-the-counter medication (Azo-Gesic, Baridium, Urinary Pain Relief) that has been used
      safely for decades as a bladder analgesic and taints the urine orange.

      Over the past few months, increasing evidence suggests that phenazopyridine may reduce
      transient postoperative urinary retention. Transient urinary retention is common after
      urogynecologic surgery and is assessed postoperatively by performing a void trial (VT) prior
      to discharge. In a study designed to determine the time from administration of oral
      phenazopyridine to visualize dye from the ureters, Propst et al incidentally found that 38%
      of patients (19 of 49) failed postoperative VTs without phenazopyridine, but only 19% (9 of
      47) failed with phenazopyridine, p=0.04. Most recently, a study by Duenas-Garcia et al
      designed to examine local anesthetics and urinary retention in subjects undergoing
      midurethral slings found that phenazopyridine decreased the VT failure rate from 30% to 8%
      (5). The investigators hypothesize that giving a dose of phenazopyridine the morning after
      surgery will significantly reduce the rate of postoperative urinary retention in women
      undergoing prolapse repair.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">August 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Postoperative Urinary Retention After Pelvic Organ Prolapse Surgery (INTENT-TO-TREAT)</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>Rate of postoperative urinary retention after pelvic organ prolapse surgery as determined by those who failed a standardized void trial. A successful void trial is defined as a postvoid residual of less than half of the voided volume.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Postoperative Urinary Retention After Pelvic Organ Prolapse Surgery (AS-TREATED)</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>Rate of postoperative urinary retention after pelvic organ prolapse surgery as determined by those who failed a standardized void trial. A successful void trial is defined as a postvoid residual of less than half of the voided volume.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Urinary Retention Postoperative</condition>
  <arm_group>
    <arm_group_label>Phenazopyridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant is given Phenazopyridine 200mg on postoperative day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Phenazopyridine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participant is not given Phenazopyridine on postoperative day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenazopyridine</intervention_name>
    <description>Phenazopyridine 200 mg on morning of postoperative day 1</description>
    <arm_group_label>Phenazopyridine</arm_group_label>
    <other_name>Pyridium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing overnight admission after prolapse surgery

        Exclusion Criteria:

          -  Unable to provide consent

          -  Under 18 years of age

          -  Pregnant women

          -  Prisoners

          -  Using intermittent self-catheterization preoperatively

          -  Neurological disease or spinal cord injury resulting in voiding dysfunction

          -  Undergoing spinal or epidural anesthesia for the procedure

          -  Allergy to phenazopyridine

          -  Renal insufficiency

          -  Liver disease

          -  Intra-operative bladder injury necessitating use of prolonged indwelling Foley
             catheter
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Flynn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <results_first_submitted>January 25, 2019</results_first_submitted>
  <results_first_submitted_qc>March 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2019</results_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Michael Flynn</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03065075/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phenazopyridine on POD1</title>
          <description>Participant is given Phenazopyridine 200 mg on postoperative day 1
76 subjects were randomized into this arm
4 were removed from the intent-to-treat analysis:
1 had a bowel injury re-operation that precluded performing a void trial
1 intraoperative cystotomy that precluded performing a void trial
2 were using Foley catheters preoperatively, which was part of the exclusion criteria
72 subjects in the intent-to-treat analysis
3 did not receive the intervention:
1 was too nauseous
1 was erroneously missed
1 refused
69 subjects in the as-treated analysis</description>
        </group>
        <group group_id="P2">
          <title>No Intervention on POD1</title>
          <description>Subject is not given Phenazopyridine on postoperative day 1
76 subjects were randomized into this arm
2 were removed from the intent-to-treat analysis:
1 intraoperative cystotomy that precluded performing a void trial
1 had spinal anesthesia, which was part of the exclusion criteria
74 subjects in the intent-to-treat analysis
3 cross-overs were brought in from the intervention arm because they did not receive the medication
77 subjects in the as-treated analysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat Analysis</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>As-treated Analysis</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phenazopyridine</title>
          <description>Participant is given Phenazopyridine on morning of postoperative day 1</description>
        </group>
        <group group_id="B2">
          <title>No Phenazopyridine</title>
          <description>Participant is not given Phenazopyridine on morning of postoperative day 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="12.8"/>
                    <measurement group_id="B2" value="60.9" spread="13.5"/>
                    <measurement group_id="B3" value="61.2" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Declined to answer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant hysterectomy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postoperative Urinary Retention After Pelvic Organ Prolapse Surgery (INTENT-TO-TREAT)</title>
        <description>Rate of postoperative urinary retention after pelvic organ prolapse surgery as determined by those who failed a standardized void trial. A successful void trial is defined as a postvoid residual of less than half of the voided volume.</description>
        <time_frame>postoperative day 1</time_frame>
        <population>Intent-to-treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Phenazopyridine</title>
            <description>Participant is given Phenazopyridine on morning of postoperative day 1</description>
          </group>
          <group group_id="O2">
            <title>No Phenazopyridine</title>
            <description>Participant is not given Phenazopyridine on morning of postoperative day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Urinary Retention After Pelvic Organ Prolapse Surgery (INTENT-TO-TREAT)</title>
          <description>Rate of postoperative urinary retention after pelvic organ prolapse surgery as determined by those who failed a standardized void trial. A successful void trial is defined as a postvoid residual of less than half of the voided volume.</description>
          <population>Intent-to-treat analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Postoperative Urinary Retention After Pelvic Organ Prolapse Surgery (AS-TREATED)</title>
        <description>Rate of postoperative urinary retention after pelvic organ prolapse surgery as determined by those who failed a standardized void trial. A successful void trial is defined as a postvoid residual of less than half of the voided volume.</description>
        <time_frame>postoperative day 1</time_frame>
        <population>As-treated analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Phenazopyridine</title>
            <description>Participant is given Phenazopyridine on morning of postoperative day 1</description>
          </group>
          <group group_id="O2">
            <title>No Phenazopyridine</title>
            <description>Participant is not given Phenazopyridine on morning of postoperative day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Urinary Retention After Pelvic Organ Prolapse Surgery (AS-TREATED)</title>
          <description>Rate of postoperative urinary retention after pelvic organ prolapse surgery as determined by those who failed a standardized void trial. A successful void trial is defined as a postvoid residual of less than half of the voided volume.</description>
          <population>As-treated analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phenazopyridine</title>
          <description>Participant is given Phenazopyridine
Phenazopyridine: Phenazopyridine on morning of postoperative day 1
76 subjects were randomized into this arm
4 were removed from the intent-to-treat analysis:
1 had a bowel injury re-operation that precluded performing a void trial
1 intraoperative cystotomy that precluded performing a void trial
2 were using Foley catheters preoperatively, which was part of the exclusion criteria
72 subjects in the intent-to-treat analysis
3 did not receive the intervention:
1 was too nauseous
1 was erroneously missed
1 refused
69 subjects in the as-treated analysis</description>
        </group>
        <group group_id="E2">
          <title>No Phenazopyridine</title>
          <description>Participant is not given Phenazopyridine
76 subjects were randomized into this arm
2 were removed from the intent-to-treat analysis:
1 intraoperative cystotomy that precluded performing a void trial
1 had spinal anesthesia, which was part of the exclusion criteria
74 subjects in the intent-to-treat analysis
3 cross-overs were brought in from the intervention arm because they did not receive the medication
77 subjects in the as-treated analysis</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel injury re-operation</sub_title>
                <description>Re-operation and ICU admission for bowel injury during prolapse surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>A positive urine culture, urinalysis, or antibiotic treatment within 6 weeks postoperatively constituted a UTI.</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tania Sierra</name_or_title>
      <organization>University of Massachusetts</organization>
      <phone>508-334-9840</phone>
      <email>tania.sierra@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

